2-(trifluoromethyl)thiobenzenemethanamine | 236736-24-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(trifluoromethyl)thiobenzenemethanamine
• 英文别名: 2-[(trifluoromethyl)thio]benzylamine；2-(Trifluoromethylthio)Benzylamine；[2-(trifluoromethylsulfanyl)phenyl]methanamine
• CAS: 236736-24-6
• 化学式: C₈H₈F₃NS
• mdl: MFCD00236343
• 分子量: 207.219
• InChiKey: YWKFKAJMVJFHMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(trifluoromethyl)thiobenzenemethanamine 生成 3-(2,3-dichlorophenyl)-4-{2-[(trifluoromethyl)thio]benzyl}-4H-1,2,4-triazole
  参考文献：
  名称：

  P2X7 receptor antagonists and methods of use

  摘要：

  这项发明涉及具有化学式(I)或(II)的P2X7拮抗剂化合物，或其药学上可接受的盐、前药、前药的盐或二者的组合，其中R1、R2和R3在规范中有定义。该发明还涉及一种选择性抑制P2X7活性的方法，包括向需要此类治疗的患者施用化合物的治疗有效量，其化学式为(III)、(IV)或(V)，其中R6、R7、R8、R9、R10和R11在规范中有定义。

  公开号：

  US20070105842A1

文献信息

• Discovery of soluble epoxide hydrolase inhibitors through DNA-encoded library technology (ELT)
  作者：Yun Ding、Svetlana Belyanskaya、Jennifer L. DeLorey、Jeffrey A. Messer、G. Joseph Franklin、Paolo A. Centrella、Barry A. Morgan、Matthew A. Clark、Steven R. Skinner、Jason W. Dodson、Peng Li、Joseph P. Marino、David I. Israel

  DOI：10.1016/j.bmc.2021.116216

  日期：2021.7

  Inhibition of soluble epoxide hydrolase (sEH) has recently emerged as a new approach to treat cardiovascular disease and respiratory disease. Inhibitors based on 1,3,5-triazine chemotype were discovered through affinity selection against two triazine-based DNA-encoded libraries. The structure and activity relationship study led to the expansion of the original 1,4-cycloalkyl series to related aniline

  可溶性环氧化物水解酶 (sEH) 的抑制最近已成为治疗心血管疾病和呼吸系统疾病的新方法。通过对两个基于三嗪的 DNA 编码文库的亲和力选择，发现了基于 1,3,5-三嗪化学型的抑制剂。结构和活性关系研究导致最初的 1,4-环烷基系列扩展到相关的苯胺、哌啶、喹啉、芳基醚和苄基系列。1,3-环烷基化学型导致了 COPD 临床候选药物 (GSK2256294) 的发现。
• 3-[(2<i>R</i>)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a Potent and Orally Active Antagonist of the Human Gonadotropin-Releasing Hormone Receptor. Design, Synthesis, and in Vitro and in Vivo Characterization
  作者：Fabio C. Tucci、Yun-Fei Zhu、R. Scott Struthers、Zhiqiang Guo、Timothy D. Gross、Martin W. Rowbottom、Oscar Acevedo、Yinghong Gao、John Saunders、Qiu Xie、Greg J. Reinhart、Xin-Jun Liu、Nicholas Ling、Anne K. L. Bonneville、Takung Chen、Haig Bozigian、Chen

  DOI：10.1021/jm049218c

  日期：2005.2.1

  antagonists of the human gonadotropin-releasing hormone receptor. Uracils bearing a side chain derived from phenylglycinol at the 3-position were shown to be orally bioavailable in monkeys. 3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (R-13b, NBI 42902) displayed subnanomolar binding affinity (K(i) = 0.56 nM) and was a potent functional antagonist

  在1、3和5位的一系列取代尿嘧啶的进一步结构-活性关系研究导致发现了人类促性腺激素释放激素受体的几种有效拮抗剂。已显示在3-位带有衍生自苯甘醇的侧链的尿嘧啶在猴子中具有口服生物利用度。3-[（2R）-氨基-2-苯基乙基] -1-（2,6-二氟苄基）-5-（2-氟-3-甲氧基苯基）-6-甲基嘧啶-2,4-二酮（R-13b， NBI 42902）显示了对人GnRH受体的亚纳摩尔结合亲和力（K（i）= 0.56 nM），是一种有效的功能拮抗剂（在Ca（2+）通量测定中，IC（50）= 3.0 nM）。它也以高亲和力（K（i）= 3.9 nM）与猴子GnRH受体结合。此外，R-13b在食蟹猕猴口服后具有良好的血浆暴露，其C（max）为737 ng / mL，AUC为2392 ng / mL。h以10 mg / kg的剂量服用。此外，对cast割的雄性食蟹猴口服R-13b会导致血清黄体生成激素水平显
• [EN] NOVEL SEH INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE SEH ET LEUR UTILISATION
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009049157A1

  公开（公告）日：2009-04-16

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及新型sEH抑制剂及其在通过sEH酶介导的疾病治疗中的应用。具体来说，该发明涉及符合以下式I的化合物：其中R1、R2、R4、R5、R6、A、B、Y、Z、n和m如下所定义，并其药学上可接受的盐。该发明的化合物是sEH抑制剂，可用于通过sEH酶介导的疾病治疗，如高血压。因此，该发明进一步涉及包含该发明的化合物的药物组合物。该发明还进一步涉及使用该发明的化合物或包含该发明的药物组合物来抑制sEH并治疗与之相关的病症的方法。
• [EN] NOVEL SEH INHIBITORS AND THEIR USE<br/>[FR] INHIBITEURS INÉDITS DE LA SEH ET LEUR UTILISATION
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009049165A1

  公开（公告）日：2009-04-16

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及新颖的sEH抑制剂及其在通过sEH酶介导的疾病治疗中的应用。具体而言，该发明涉及符合以下式I的化合物：(I) 其中R1、R2、R3、R5a、R6a、A、B、Y、x和m的定义如下，并且其药用盐。该发明的化合物是sEH抑制剂，可用于治疗通过sEH酶介导的疾病，如高血压。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制sEH和治疗与之相关的疾病的方法。
• Novel sEH Inhibitors and Their Use
  申请人：Ding Yun

  公开号：US20100069391A1

  公开（公告）日：2010-03-18

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.

  本发明涉及新型sEH抑制剂及其在治疗由sEH酶介导的疾病中的应用。